Data mining of the public version of the FDA Adverse Event Reporting System
- PMID: 23794943
- PMCID: PMC3689877
- DOI: 10.7150/ijms.6048
Data mining of the public version of the FDA Adverse Event Reporting System
Abstract
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.
Keywords: Adverse Event Reporting System; FAERS; adverse event; data mining; database; empirical Bayes geometric mean; information component; pharmacoepidemiology; pharmacovigilance.; proportional reporting ratio; reporting odds ratio; signal; signal detection.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Similar articles
-
Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.Int J Med Sci. 2014 Mar 15;11(5):461-5. doi: 10.7150/ijms.7967. eCollection 2014. Int J Med Sci. 2014. PMID: 24688309 Free PMC article.
-
Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Mar 28;48(3):422-434. doi: 10.11817/j.issn.1672-7347.2023.220304. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37164926 Free PMC article. Chinese, English.
-
Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.Expert Opin Drug Saf. 2024 Oct;23(10):1317-1325. doi: 10.1080/14740338.2024.2382226. Epub 2024 Jul 19. Expert Opin Drug Saf. 2024. PMID: 39021273
-
Anaphylaxis associated with gadolinium-based contrast agents: data from the Food and Drug Administration's Adverse Event Reporting System and review of case reports in the literature.Expert Opin Drug Saf. 2014 Jan;13(1):15-23. doi: 10.1517/14740338.2013.832752. Epub 2013 Sep 20. Expert Opin Drug Saf. 2014. PMID: 24053773 Review.
-
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.Drug Saf. 2018 Apr;41(4):357-361. doi: 10.1007/s40264-017-0622-2. Drug Saf. 2018. PMID: 29196988 Review.
Cited by
-
Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data.Front Med (Lausanne). 2024 Oct 18;11:1412700. doi: 10.3389/fmed.2024.1412700. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39493722 Free PMC article.
-
Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database.J Pharm Health Care Sci. 2016 Jun 21;2:14. doi: 10.1186/s40780-016-0048-5. eCollection 2016. J Pharm Health Care Sci. 2016. PMID: 27330825 Free PMC article.
-
Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events.J Med Internet Res. 2016 Apr 1;18(4):e76. doi: 10.2196/jmir.4541. J Med Internet Res. 2016. PMID: 27036325 Free PMC article.
-
Dexmedetomidine: a real-world safety analysis based on FDA adverse event reporting system database.Front Pharmacol. 2024 Aug 23;15:1419196. doi: 10.3389/fphar.2024.1419196. eCollection 2024. Front Pharmacol. 2024. PMID: 39246655 Free PMC article.
-
Effectiveness of a structured stimulated spontaneous safety monitoring of medicines reporting program in strengthening pharmacovigilance system in Tanzania.Sci Rep. 2022 Sep 27;12(1):16131. doi: 10.1038/s41598-022-19884-0. Sci Rep. 2022. PMID: 36167960 Free PMC article.
References
-
- Rodriguez EM, Staffa JA, Graham DJ. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf. 2001;10:407–410. - PubMed
-
- Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:1363–1369. - PubMed
-
- U.S. Food and Drug Administration (FDA) http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveil.... - PubMed
-
- MedDRA MSSO. http://www.meddramsso.com/index.asp.
-
- Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med. 2007;167:1752–1759. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources